 |
|
|
| |
Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial
|
| |
| |
Reported by Jules Levin
IDWeek 2019™, October 2-6, 2019, Washington, DC
David A. Wohl,1 Peter J. Ruane,2 Sybil Hosek,3 Catherine M. Creticos,4 Sheldon Morris,5 John Phoenix,6 Moti N. Ramgopal,7 Cynthia Brinson,8 Cecile Tremblay,9 Christoph C. Carter,10 Pamela Wong,10 Diana M. Brainard,10 Scott McCallister,10 Moupali Das,10 Melanie A. Thompson11
1University of North Carolina at Chapel Hill School of Medicine; 2Ruane Clinical Research Group, Inc., Los Angeles, CA; 3John H. Stroger, Jr. Hospital of Cook County, Chicago, IL; 4Howard Brown Health, Chicago; 5UC San Diego School of Medicine, La Jolla, CA; 6Huntridge Family Clinic, Las Vegas, NV; 7Midway Research Center, Fort Pierce, FL; 8Central Texas Clinical Research, Austin, TX; 9Centre Hospitalier de l'Universite de Montreal, Quebec, Canada; 10Gilead Sciences, Inc., Foster City, CA; 11AIDS Research Consortium of Atlanta, GA
*From rank analysis of covariance adjusting for baseline BMD clinical status and baseline F/TDF for PrEP to compare treatments.
References: 1. Ruane P, et al. J Acquir Immune Defic Syndr 2013;63:449-55; 2. Sax P, et al. J Acquir Immune Defic Syndr 2014;67:52-8; 3. Arribas J, et al. J Acquir Immune Defic Syndr 2017;75:211-8; 4. Borges AH, et al. Clin Infect Dis 2017;64:1413-21; 5. Weaver CM, et al. Osteoporos Int 2016;27:1281-386; 6. Chou R, et al. JAMA 2019;321:2214-30.
Acknowledgments: We extend our thanks to the participants, their families, and all participating study investigators and staff: Austria: B Haas, A Rieger; Canada: J Brunetta, JJ de Wet, J Szabo, C Tremblay, B Trottier; Denmark: J Gerstoft, G Kronborg, C Larsen, D Larsen; France: E Cua, J-M Molina, P Philibert, G Pialoux; Germany: H Jessen, G Knecht, I Krznaric, C Spinner; Ireland: C Bergin, P Mallon; Italy: A Antinori, A Lazzarin; Netherlands: M Prins; Spain: J Coll, M Crespo, J del Romero Gerrero, D Podzamczer; UK: V Apea, A Clarke, O Dosekun, R Gilson, S Kegg, C Leen, N Nwokolo, F Post, I Reeves, G Schembri, S Taylor; USA: D Asmuth, A Avery, P Benson, M Berhe, I Brar, C Brinson, JH Burack, T Campbell, M Cespedes, M Coleman, CM Creticos, GE Crofoot, FA Cruickshank, E Daar, E DeJesus, W Dinges, S Doblecki-Lewis, T Donovan, J Flamm, JE Gallant, J Gladstein, RM Grant, R Grossberg, J Halperin, WD Hardy, CB Hare, S Hassler, R Hengel, K Henry, T Hodge, S Hosek, M Iandorio, A LaMarca, C Lucasti, S Mannheimer, CT Martorell, M Markowitz, K Mayer, A Mills, S Morris, K Mounzer, O Ogbuagu, O Osiyemi, A Petroll, J Phoenix, MN Ramgopal, B Rashbaum, GJ Richmond, PJ Ruane, L Salazar, AJ Scarsella, M Scott, P Shalit, JL Stephens, MA Thompson, G Voskuhl, BH Wade, DA Wohl, K Workowski, B Young. This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
